Data analytics company Trayt has unveiled mobile application to enhance diagnosis, treatment and quality of life for patients with autism, ADHD and neurodevelopmental disorders.
The company announced the public availability of its mobile application, which allows patients and caretakers to track behavioral and non-behavioral symptoms via its patent pending comorbid rating scale and to exactly measure effectiveness of their treatments.
The data will then be analyzed and presented in a dashboard with progress reports and personalized and actionable insights.
Trayt stated that more often patients with brain-based disorders are often diagnosed and treated by disjointed care teams that take decisions based on a narrow set of symptoms which do not address the connections between the brain and body.
Lack of visibility into the patient’s overlapping conditions and treatments have resulted in the inability to optimize care for unique needs of each patient. To solve this issue, Trayt has integrated diagnostic manuals and evidence-based research to create a comorbid assessment rating scale and an analytic engine.
With a standardized measurement and a holistic view of looking into all factors contributing to the outcomes, is expected to offer significant improvement and reduction in costs across the entire system of healthcare.
Trayt founder and CEO Malekeh Amini said: "Trayt was designed to treat patients holistically and to date, our team has received tremendous support from the medical community and from users in our pilot program; a true testament to the significance of the challenges we are trying to solve and the ability of our solution to address those challenges.
"The public launch of our application is an incredible milestone towards achieving our goal of transforming the system of care in brain-based disorders and improving patient outcomes.”
Trayt has showcased the app at EdRev Expo at AT&T Park in San Francisco on 21 April 2018.
Trayt Technologies is a patient-centric data analytics firm that seeks to enhance diagnosis, treatments and quality of life for patients with autism, ADHD and other neurodevelopmental and brain disorders.
The company plans to acheive its goals by creating tools to measure efficacy of all interventions and by engaging the entire system of care to continuously track, measure and share behavioral and medical outcomes.